Company intelligence / Profile preview

TauMark

La Jolla, California, USA

Ownership: Private
Development stage: Other

Overview

TauMark is a biotechnology company dedicated to the development of innovative diagnostic and therapeutic agents for neurodegenerative diseases, with a primary focus on tauopathies such as Alzheimer's disease. The company leverages its expertise in tau protein biology to identify and advance small molecule ligands for positron emission tomography (PET) imaging. These tools are designed to enable early detection, accurate staging, and monitoring of disease progression. TauMark's research aims to bridge the gap between molecular pathology and clinical diagnosis to facilitate the development of effective treatments.

Therapeutic areas: Neurology
Modalities: Small moleculeRadiopharmaceutical
Industry: Biotech

Partnerships

Siemens Molecular Imaging

Beyond the preview

Go deeper on TauMark.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TauMark.

Explore the full profile